In conclusion, this study provides the first evidence to support a better outcome for p16-positive HNSCC patients when treated with RT combined with EGFR inhibitors vs. RT combined with traditional cisplatin-based CT. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.